Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: BlueCrab who wrote (7582)	9/28/1999 1:30:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 8116

Cytogen To Acquire License To Develop Antigen Tests PRINCETON, N.J. -- Cytogen Corp. (CYTO) signed a letter of intent to acquire the exclusive license for Molecular Staging Inc.'s Rolling Circle Amplification Technology. Financial terms weren't disclosed. In a press release Tuesday, Cytogen said it will use the technology to develop in-vitro diagnostic tests for prostate specific membrane antigen and prostate specific antigen. The biopharmaceutical company said it should have an assay for clinical study by mid-2000. Locating the antigens helps physicians identify prostate cancer, said Cytogen Jim